Policy UpdatesMedicare AdvantageJune 29, 2023

Clinical Criteria updates - March 2023

Clinical Criteria updates

On August 19, 2022, and March 23, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits. 

Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.

Please see the explanation/definition for each category of Clinical Criteria below:

  • New: Newly published criteria
  • Revised: Addition or removal of medical necessity requirements, new document number
  • Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.

Please share this notice with other providers in your practice and office staff.

Please note:

  • The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
  • This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.

Effective date

Clinical Criteria  number

Clinical Criteria title

New or revised

August 6, 2023

*CC-0235

Revcovi (elapegademase-lvlr)

New

August 6, 2023

*CC-0236

Signifor LAR (pasireotide)

New

August 6, 2023

CC-0125

Opdivo (nivolumab)

Revised

August 6, 2023

CC-0072

Vascular Endothelial Growth Factor (VEGF) Inhibitors

Revised

August 6, 2023

CC-0038

Human Parathyroid Hormone Agents

Revised

August 6, 2023

CC-0066

Monoclonal Antibodies to Interleukin-6

Revised

August 6, 2023

*CC-0197

Jemperli (dostarlimab-gxly)

Revised

August 6, 2023

*CC-0119

Yervoy (ipilimumab)

Revised

August 6, 2023

CC-0092

Adcetris (brentuximab vedotin)

Revised

August 6, 2023

*CC-0065

Hemophilia A and von Willebrand Disease

Revised

August 6, 2023

*CC-0034

Agents for Hereditary Angioedema

Revised

August 6, 2023

CC-0061

GnRH Analogs for the Treatment of Non-Oncologic Indications

Revised

August 6, 2023

CC-0008

Subcutaneous Hormonal Implants

Revised

August 6, 2023

CC-0026

Testosterone, Injectable

Revised

MULTI-BCBS-CR-027354-23-CPN26411

PUBLICATIONS: August 2023 Provider Newsletter